As the popularity of weight-loss drugs like Ozempic continues to grow, Galderma, a Swiss pharmaceutical company known for its skin care treatments, sees an opportunity to increase demand for its facial fillers products. The CEO believes that the sunken-in look that some patients experience with Ozempic can be counteracted by fillers like Sculptra.
To evaluate the effects of Sculptra and Restylane for cheek augmentation and contour deficiencies in patients using GLP-1 treatments, Galderma has started a study. Enrollment is ongoing, and results may be available by the end of the year.
Dermatologists have noted that “Ozempic face” has become increasingly common in their practices due to the widespread use of weight-loss medications. The term refers to the sunken and aged appearance that can result from rapid weight loss.
Galderma, which went public last month on the SIX Swiss Exchange, reported a 12.4% increase in sales year-over-year in the first quarter of the year. The company also owns popular drug store brand Cetaphil. The CEO remains optimistic about the growth potential in the fillers market and plans to capitalize on the trend of weight-loss drugs like Ozempic.
